Listed Companies > Listed Companies Info. > Main Board Companies > Listed Company Profile
General Stock Board Listed Company Profile
Local/Foreign Company:
4726 Mycenax
Company Profile
Chairman CEO Spokesperson Tel Address Date of Listing (Regular)
Jung-chin Lin Pei-Jiun Chen Pei-Jiun Chen 037586988 2F No 8 Kedung 3 RoadChunan, Miaoli, Taiwan 2013/12/25
Industry Main Business
Biotechnology and Medical Care
Mycenax uses its process development technology and cGMP manufacturing capability in its biological products development and contract development services. Two products (TuNEX, Tumor Necrosis Factor Receptor-Fc and GranNEX, Granulocyte Colony Stimulating Factor) pursue Taiwan IND application in 2006 and start clinical trials in 2007. Other products, through cooperation with collaborators, in the pipeline includes Erithropoitin and anti-her2 human antibody products. Mycenax will expand its successful experiences to new protein drugs development. Mycenax specializes in strategic planning and execution, process development and manufacturing to accelerate the drug development process and minimize expenses.
Market Information ( 2020/07/08 )
Shr. Vol. Highest Lowest Closed Change Transaction TurnOver(%) long
3271.352 56.30  54.10  56.30  5.10  1545 2.55 N/A N/A
Trading method Fun
price or
on T day
Announcement of Irregularity
TPEx measures
With warrants Can be shorted or margined? Detail
Normal N Y N N N Today History
Financial Reports
Cash Flows Items
(NT$ thousand)
Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Current assets
Non-current assets
Total assets
Current liabilities
Non-current liabilities
Total liabilities
Share capital
Capital surplus
Retained earnings
Other equity interest
Treasury shares
Total equity attributable to owners of parent
Non-controlling interests
Total equity
Book Value per share(NT$)
Comprehensive Income Operating revenue
Operating costs
Gross profit from operations
Operating expenses
Net other income (expenses)
Net operating income
Non-operating income and expenses
Profit before tax
Tax expense
Profit from continuing operations
Profit from discontinued operations
Other comprehensive income
Comprehensive income
Basic earnings per share
* Auditor's report on latest financial statements: auditor's report:
* More detail:MOPS
* Foreign issuers’ information is disclosed in consolidated statements.